Insider & Institutional Ownership
78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 16.4% of Chromocell Therapeutics shares are held by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Chromocell Therapeutics has a beta of 3.63, meaning that its stock price is 263% more volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500.
Earnings & Valuation
This table compares Chromocell Therapeutics and SQZ Biotechnologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Chromocell Therapeutics | N/A | N/A | -$7.38 million | ($1.24) | -1.08 |
| SQZ Biotechnologies | $18.16 million | 0.05 | -$79.46 million | ($2.61) | -0.01 |
Chromocell Therapeutics has higher earnings, but lower revenue than SQZ Biotechnologies. Chromocell Therapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Chromocell Therapeutics and SQZ Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Chromocell Therapeutics | N/A | N/A | -453.90% |
| SQZ Biotechnologies | -369.96% | -119.83% | -59.90% |
Summary
Chromocell Therapeutics beats SQZ Biotechnologies on 7 of the 10 factors compared between the two stocks.
About Chromocell Therapeutics
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Chromocell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromocell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
